Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Daiichi Sankyo
Queensland Health
Moodys
Fish and Richardson
Federal Trade Commission
UBS
AstraZeneca
Colorcon
US Department of Justice

Generated: October 20, 2017

DrugPatentWatch Database Preview

CICLOPIROX Drug Profile

« Back to Dashboard

What is the patent landscape for Ciclopirox, and when can generic versions of Ciclopirox launch?

Ciclopirox is a drug marketed by Cnty Line Pharms, Fougera Pharms, Perrigo New York, Cipla Ltd, G And W Labs, Taro Pharm Inds, Actavis Mid Atlantic, G And W Labs Inc, Paddock Llc, Mylan Pharms Inc, Taro, Hi Tech Pharma, Apotex Inc, Glenmark Pharms, Akorn, Teva Pharms, Tolmar, Perrigo Co, and Glenmark Generics. and is included in twenty-seven NDAs. There are two patents protecting this drug.

This drug has forty-three patent family members in thirty-four countries.

The generic ingredient in CICLOPIROX is ciclopirox. There are ten drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the ciclopirox profile page.

Summary for Tradename: CICLOPIROX

US Patents:2
Applicants:19
NDAs:27
Suppliers / Packagers: see list20
Bulk Api Vendors: see list54
Clinical Trials: see list9
Patent Applications: see list3,031
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:CICLOPIROX at DailyMed

Pharmacology for Tradename: CICLOPIROX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fougera Pharms
CICLOPIROX
ciclopirox
GEL;TOPICAL077896-001Jun 10, 2008ABRXNoNo► Subscribe► Subscribe► Subscribe
Cnty Line Pharms
CICLOPIROX
ciclopirox
GEL;TOPICAL020519-001Jul 21, 1997ABRXYesYes► Subscribe► Subscribe ► Subscribe
Glenmark Pharms
CICLOPIROX
ciclopirox
CREAM;TOPICAL090273-001Nov 10, 2009ABRXNoNo► Subscribe► Subscribe► Subscribe
Actavis Mid Atlantic
CICLOPIROX
ciclopirox
SHAMPOO;TOPICAL090490-001Nov 24, 2009ATRXNoNo► Subscribe► Subscribe► Subscribe
Fougera Pharms
CICLOPIROX
ciclopirox
CREAM;TOPICAL076435-001Dec 29, 2004ABRXNoNo► Subscribe► Subscribe► Subscribe
Perrigo New York
CICLOPIROX
ciclopirox
SOLUTION;TOPICAL077623-001Sep 18, 2007ATRXNoNo► Subscribe► Subscribe► Subscribe
Perrigo New York
CICLOPIROX
ciclopirox
CREAM;TOPICAL077364-001Mar 3, 2006ABRXNoNo► Subscribe► Subscribe► Subscribe
Perrigo New York
CICLOPIROX
ciclopirox
SUSPENSION;TOPICAL077676-001Dec 15, 2006ABRXNoNo► Subscribe► Subscribe► Subscribe
Taro Pharm Inds
CICLOPIROX
ciclopirox
SOLUTION;TOPICAL078144-001Sep 18, 2007ATRXNoNo► Subscribe► Subscribe► Subscribe
Akorn
CICLOPIROX
ciclopirox
SOLUTION;TOPICAL078975-001Feb 17, 2010ATRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: CICLOPIROX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cnty Line Pharms
CICLOPIROX
ciclopirox
GEL;TOPICAL020519-001Jul 21, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: CICLOPIROX

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
► Subscribe
CICLOPIROX
► Subscribe

International Patent Family for Tradename: CICLOPIROX

Country Document Number Estimated Expiration
Germany19639816► Subscribe
Portugal928192► Subscribe
Cyprus2371► Subscribe
Brazil9711559► Subscribe
China1149992► Subscribe
African Intellectual Property Organization (OAPI)11026► Subscribe
Argentina008858► Subscribe
Australia718837► Subscribe
European Patent Office0928192► Subscribe
Morocco24331► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Medtronic
Deloitte
Teva
Fuji
UBS
Express Scripts
QuintilesIMS
Novartis
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot